As ri­vals look to carve up its block­buster rev­enue, No­var­tis’ Cosen­tyx reg­is­ters re­mark­ably con­sis­tent ef­fect for pso­ri­a­sis

A decade af­ter the very first pso­ri­a­sis pa­tient was treat­ed with Cosen­tyx (se­cuk­inum­ab), No­var­tis is rolling out a fresh set of da­ta un­der­scor­ing just how durable the re­sponse rates are among pa­tients tak­ing the ther­a­py.

In a 5-year fol­lowup, re­searchers for No­var­tis $NVS say that skin clear­ance rates have re­mained vir­tu­al­ly un­changed for this IL-17A block­buster. Look­ing at PASI 75/90/100, the one-year scores were 89%, 69% and 44%. At year five the PASI rates lined up at 89%, 66% and 41%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.